Kamlendra Singh

Dr. Kamlendra Singh

Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SKSaathvik R. Kannan
Saathvik R. Kannan
ASAustin N. Spratt
Austin N. Spratt
ACAlisha R. Cohen
Alisha R. Cohen
SNS. Hasan Naqvi
S. Hasan Naqvi
HCHitendr Chand
Hitendr Chand
Kamlendra SinghKamlendra Singh
Kamlendra Singh

13 December 2021 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SKSaathvik R. Kannan
Saathvik R. Kannan
ASAustin N. Spratt
Austin N. Spratt
KSKalicharan Sharma
Kalicharan Sharma
HCHitendra S. Chand
Hitendra S. Chand
SBSiddappa Byrareddy
Siddappa Byrareddy
Kamlendra SinghKamlendra Singh
Kamlendra Singh

11 February 2010 in Viruses
Verified
Journal Article
Open access
PDF file
Kamlendra SinghKamlendra Singh
Kamlendra Singh
BMBruno Marchand
Bruno Marchand
KKKaren Kirby
Karen Kirby
EMEleftherios Michailidis
Eleftherios Michailidis
SSStefan Sarafianos
Stefan Sarafianos
HIV-1 Reverse Transcriptase (HIV-1 RT) has been the target of numerous approved anti-AIDS drugs that are key components of Highly Active Anti-Retroviral Therapies (HAART). It remains the target of extensive structural studies that continue unabated for almost twenty years. The crystal structures of wild-type or drug-resistant mutant HIV RTs in the unliganded form or in complex with substrates and/or drugs have offered valuable glimpses into the enzyme’s folding and its interactions with DNA and dNTP substrates, as well as with nucleos(t)ide reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTIs) drugs. These studies have been used to interpret a large body of biochemical results and have paved the way for innovative biochemical experiments designed to elucidate the mechanisms of catalysis and drug inhibition of polymerase and RNase H functions of RT. In turn, the combined use of structural biology and biochemical approaches has led to the discovery of novel mechanisms of drug resistance and has contributed to the design of new drugs with improved potency and ability to suppress multi-drug resistant strains.

20 June 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
Kamlendra SinghKamlendra Singh
Kamlendra Singh
FGFabio Gallazzi
Fabio Gallazzi
KHKyle Hill
Kyle Hill
DBDonald H. Burke
Donald H. Burke
MLMargaret Lange-Osborn
Margaret Lange-Osborn
ASAnders Sönnerborg
Anders Sönnerborg
Recently reported HIV-1 capsid (CA) inhibitors GS-CA1 and GS-6207 (an analog of GS-CA1) are first-in-class compounds with long-acting potential. Reportedly, both compounds have greater potency than currently approved anti-HIV drugs. Due to the limited access to experimental data and the compounds themselves, a detailed mechanism of their inhibition is yet to be delineated. Using crystal structures of capsid-hexamers bound to well-studied capsid inhibitor PF74 and molecular modeling, we predict that GS-CA compounds bind in the pocket that is shared by previously reported CA inhibitors and host factors. Additionally, comparative modeling suggests that GS-CA compounds have unique structural features contributing to interactions with capsid. To test their proposed binding mode, we also report the design of a cyclic peptide combining structural units from GS-CA compounds, host factors, and previously reported capsid inhibitors. This peptide (Pep-1) binds CA-hexamer with a docking score comparable to GS-CA compounds. Affinity determination by MicroScale thermophoresis (MST) assays showed that CA binds Pep-1 with a ~7-fold better affinity than well-studied capsid inhibitor PF74, suggesting that it can be developed as a possible CA inhibitor.

14 October 2022 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SKSaathvik R. Kannan
Saathvik R. Kannan
SSShrikesh Sachdev
Shrikesh Sachdev
ARAthreya S. Reddy
Athreya S. Reddy
SKShree Lekha Kandasamy
Shree Lekha Kandasamy
SBSiddappa N. Byrareddy
Siddappa N. Byrareddy
Kamlendra SinghKamlendra Singh
Kamlendra Singh

3 April 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Open access
ASAustin N. Spratt
Austin N. Spratt
FGFabio Gallazzi
Fabio Gallazzi
TQThomas P. Quinn
Thomas P. Quinn
CLChristian L. Lorson
Christian L. Lorson
ASAnders Sönnerborg
Anders Sönnerborg
Kamlendra SinghKamlendra Singh
Kamlendra Singh
Introduction: Coronaviruses encode a helicase that is essential for viral replication and represents an excellent antiviral target. However, only a few coronavirus helicase inhibitors have been patented. These patents include drug-like compound SSYA10-001, aryl diketo acids (ADK), and dihydroxychromones. Additionally, adamantane-derived bananins, natural flavonoids, one acrylamide derivative [(E)-3-(furan-2-yl)-N-(4-sulfamoylphenyl)acrylamide], a purine derivative (7-ethyl-8-mercapto-3-methyl-3,7-dihydro-1 H-purine-2,6-dione), and a few bismuth complexes. The IC50 of patented inhibitors ranges between 0.82 μM and 8.95 μM, depending upon the assays used. Considering the urgency of clinical interventions against Coronavirus Disease-19 (COVID-19), it is important to consider developing antiviral portfolios consisting of small molecules. Areas covered: This review examines coronavirus helicases as antiviral targets, and the potential of previously patented and experimental compounds to inhibit the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) helicase. Expert opinion: Small molecule coronavirus helicase inhibitors represent attractive pharmacological modalities for the treatment of coronaviruses such as SARS-CoV and SARS-CoV-2. Rightfully so, the current emphasis is focused upon the development of vaccines. However, vaccines may not work for everyone and broad-based adoption of vaccinations is an increasingly challenging societal endeavor. Therefore, it is important to develop additional pharmacological antivirals against the highly conserved coronavirus helicases to broadly protect against this and subsequent coronavirus epidemics.